Summary:
The primary objective of the study is to assess the safety and tolerability of AMG 890 when administered subcutaneously (SC) as a single dose to individuals who have elevated plasma Lipoprotein(a) (Lp[a]).
Qualified Participants Must:
• Must be 18-65 years of age
•
Males and Females -Only women unable to become pregnant (that is, women who are postmenopausal or have had surgery to remove their uterus or both ovaries or both fallopian tubes) may participate in this study.
•
Must be on a stable dose of cholesterol medication for at least 6 weeks at the time of enrollment
•
Willing to commit to a long-term study with 18 outpatient visits.
Qualified Participants May Receive:
Compensation is up to $3,050